Cargando…

A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors

PURPOSE: To unravel the oncogenic role of CDCA4 in different cancers from the perspective of tumor immunity. METHODS: Raw data on CDCA4 expression in tumor samples and paracancerous samples were obtained from TCGA and GTEX databases. In addition, we investigated pathological stages and the survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Hui, Sheng, Shuyan, Chen, Bangjie, Wang, Jianpeng, Mao, Deshen, Han, Yanxun, Liu, Yuchen, Wang, Xinyi, Gui, Siyu, Zhang, Tongyuan, Zhang, Lizhi, Li, Conghan, Hu, Xinyang, Deng, Wanyu, Liu, Xin, Xu, Honghai, Xu, Wentao, Wang, Xingyu, Liu, Rongqiang, Kong, Weihao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891459/
https://www.ncbi.nlm.nih.gov/pubmed/35251007
http://dx.doi.org/10.3389/fimmu.2022.826337
_version_ 1784661884002107392
author Fang, Hui
Sheng, Shuyan
Chen, Bangjie
Wang, Jianpeng
Mao, Deshen
Han, Yanxun
Liu, Yuchen
Wang, Xinyi
Gui, Siyu
Zhang, Tongyuan
Zhang, Lizhi
Li, Conghan
Hu, Xinyang
Deng, Wanyu
Liu, Xin
Xu, Honghai
Xu, Wentao
Wang, Xingyu
Liu, Rongqiang
Kong, Weihao
author_facet Fang, Hui
Sheng, Shuyan
Chen, Bangjie
Wang, Jianpeng
Mao, Deshen
Han, Yanxun
Liu, Yuchen
Wang, Xinyi
Gui, Siyu
Zhang, Tongyuan
Zhang, Lizhi
Li, Conghan
Hu, Xinyang
Deng, Wanyu
Liu, Xin
Xu, Honghai
Xu, Wentao
Wang, Xingyu
Liu, Rongqiang
Kong, Weihao
author_sort Fang, Hui
collection PubMed
description PURPOSE: To unravel the oncogenic role of CDCA4 in different cancers from the perspective of tumor immunity. METHODS: Raw data on CDCA4 expression in tumor samples and paracancerous samples were obtained from TCGA and GTEX databases. In addition, we investigated pathological stages and the survival analysis of CDCA4 in pan-cancer across Gene Expression Profiling Interactive Analysis (GEPIA) database. Cox Proportional Hazards Model shows that high CDCA4 levels are associated with several vital indicators in oncology. On the one hand, we explored the correlation between CADA4 expression and tumor immune infiltration by the TIMER tool; On the other hand, we utilized the methods of CIBERSORT and ESTIMATE computational to evaluate the proportion of tumor infiltrating immune cells (TIIC) and the amounts of stromal and immune components based on TCGA database. The use of antineoplastic drugs and the expression of CDCA4 also showed a high correlation via linear regression. Protein–Protein Interaction analysis was performed in the GeneMANIA database, and enrichment analysis was performed and predicted signaling pathways were identified by using Gene Ontology and Kyoto Encyclopedia of Genes. The correlation between CDCA4 expression with Copy number variations (CNV) and methylation is detailed, respectively. Molecular biology experiments including Western blotting, flow cytometry, EDU staining, Transwell and Wound Healing assay to validate the cancer promoting role of CDCA4 in hepatocellular carcinoma (HCC). RESULTS: Most tumors highly expressed CDCA4. Elevated CDCA4 expression was associated with poor OS and DFS. There was a significant correlation between CDCA4 expression and TITCs. Moreover, markers of TIICs exhibited distinct patterns of CDCA4 associated immune infiltration. In addition, we pay attention to the association between the expression of CDCA4 and the use of the anti-tumor drugs. CDCA4 is related to biological progress (BP), cellular component (CC) and molecular function (MF). Dopaminergic Synapse, AMPK, Sphingolipid, Chagas Disease, mRNA Surveillance were significantly enriched pathways in positive and negative correlation genes with CDCA4. CNV is thought to be a positive correlation with CDCA4 expression. Conversely, methylation is negative correlation with CDCA4 expression. Molecular biology experiments confirm a cancer promoting role for CDCA4 in HCC CONCLUSION: CDCA4 may serve as a biomarker for cancer immunologic infiltration and poor prognosis, providing a new way of thinking for cancer treatment.
format Online
Article
Text
id pubmed-8891459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88914592022-03-04 A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors Fang, Hui Sheng, Shuyan Chen, Bangjie Wang, Jianpeng Mao, Deshen Han, Yanxun Liu, Yuchen Wang, Xinyi Gui, Siyu Zhang, Tongyuan Zhang, Lizhi Li, Conghan Hu, Xinyang Deng, Wanyu Liu, Xin Xu, Honghai Xu, Wentao Wang, Xingyu Liu, Rongqiang Kong, Weihao Front Immunol Immunology PURPOSE: To unravel the oncogenic role of CDCA4 in different cancers from the perspective of tumor immunity. METHODS: Raw data on CDCA4 expression in tumor samples and paracancerous samples were obtained from TCGA and GTEX databases. In addition, we investigated pathological stages and the survival analysis of CDCA4 in pan-cancer across Gene Expression Profiling Interactive Analysis (GEPIA) database. Cox Proportional Hazards Model shows that high CDCA4 levels are associated with several vital indicators in oncology. On the one hand, we explored the correlation between CADA4 expression and tumor immune infiltration by the TIMER tool; On the other hand, we utilized the methods of CIBERSORT and ESTIMATE computational to evaluate the proportion of tumor infiltrating immune cells (TIIC) and the amounts of stromal and immune components based on TCGA database. The use of antineoplastic drugs and the expression of CDCA4 also showed a high correlation via linear regression. Protein–Protein Interaction analysis was performed in the GeneMANIA database, and enrichment analysis was performed and predicted signaling pathways were identified by using Gene Ontology and Kyoto Encyclopedia of Genes. The correlation between CDCA4 expression with Copy number variations (CNV) and methylation is detailed, respectively. Molecular biology experiments including Western blotting, flow cytometry, EDU staining, Transwell and Wound Healing assay to validate the cancer promoting role of CDCA4 in hepatocellular carcinoma (HCC). RESULTS: Most tumors highly expressed CDCA4. Elevated CDCA4 expression was associated with poor OS and DFS. There was a significant correlation between CDCA4 expression and TITCs. Moreover, markers of TIICs exhibited distinct patterns of CDCA4 associated immune infiltration. In addition, we pay attention to the association between the expression of CDCA4 and the use of the anti-tumor drugs. CDCA4 is related to biological progress (BP), cellular component (CC) and molecular function (MF). Dopaminergic Synapse, AMPK, Sphingolipid, Chagas Disease, mRNA Surveillance were significantly enriched pathways in positive and negative correlation genes with CDCA4. CNV is thought to be a positive correlation with CDCA4 expression. Conversely, methylation is negative correlation with CDCA4 expression. Molecular biology experiments confirm a cancer promoting role for CDCA4 in HCC CONCLUSION: CDCA4 may serve as a biomarker for cancer immunologic infiltration and poor prognosis, providing a new way of thinking for cancer treatment. Frontiers Media S.A. 2022-02-17 /pmc/articles/PMC8891459/ /pubmed/35251007 http://dx.doi.org/10.3389/fimmu.2022.826337 Text en Copyright © 2022 Fang, Sheng, Chen, Wang, Mao, Han, Liu, Wang, Gui, Zhang, Zhang, Li, Hu, Deng, Liu, Xu, Xu, Wang, Liu and Kong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Fang, Hui
Sheng, Shuyan
Chen, Bangjie
Wang, Jianpeng
Mao, Deshen
Han, Yanxun
Liu, Yuchen
Wang, Xinyi
Gui, Siyu
Zhang, Tongyuan
Zhang, Lizhi
Li, Conghan
Hu, Xinyang
Deng, Wanyu
Liu, Xin
Xu, Honghai
Xu, Wentao
Wang, Xingyu
Liu, Rongqiang
Kong, Weihao
A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title_full A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title_fullStr A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title_full_unstemmed A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title_short A Pan-Cancer Analysis of the Oncogenic Role of Cell Division Cycle-Associated Protein 4 (CDCA4) in Human Tumors
title_sort pan-cancer analysis of the oncogenic role of cell division cycle-associated protein 4 (cdca4) in human tumors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891459/
https://www.ncbi.nlm.nih.gov/pubmed/35251007
http://dx.doi.org/10.3389/fimmu.2022.826337
work_keys_str_mv AT fanghui apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT shengshuyan apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT chenbangjie apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangjianpeng apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT maodeshen apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT hanyanxun apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liuyuchen apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangxinyi apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT guisiyu apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT zhangtongyuan apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT zhanglizhi apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liconghan apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT huxinyang apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT dengwanyu apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liuxin apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT xuhonghai apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT xuwentao apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangxingyu apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liurongqiang apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT kongweihao apancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT fanghui pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT shengshuyan pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT chenbangjie pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangjianpeng pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT maodeshen pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT hanyanxun pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liuyuchen pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangxinyi pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT guisiyu pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT zhangtongyuan pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT zhanglizhi pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liconghan pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT huxinyang pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT dengwanyu pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liuxin pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT xuhonghai pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT xuwentao pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT wangxingyu pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT liurongqiang pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors
AT kongweihao pancanceranalysisoftheoncogenicroleofcelldivisioncycleassociatedprotein4cdca4inhumantumors